Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07154823 · ClinicalTrials.gov registry record
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
A clinical trial of Follicular Lymphoma (FL) and Acute Myeloid Leukaemia (AML), sponsored by Tempus AI.
- Recruiting
- Registry status
- 550
- Enrollment target
- 5
- Study locations
NCT07154823 is a study of Follicular Lymphoma (FL) and Acute Myeloid Leukaemia (AML) that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 550 participants, above the 477-participant average among 10 other Follicular Lymphoma (FL) trials with a reported enrollment target (15% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT07154823, a study of Follicular Lymphoma (FL) and Acute Myeloid Leukaemia (AML), is actively recruiting participants, sponsored by Tempus AI.
- RECRUITING
- Registry status
- 550 participants
- Enrollment target
- 5
- Study locations
Study Summary
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.
Conditions Studied
Interventions
- OTHER None - Observational Study
Study Locations (5)
Maryland
- The Center for Cancer and Blood Disorders - Bethesda
Nevada
- Cancer Care Specialists of Reno - Reno
Ohio
- Taylor Cancer Research Center - Maumee
Pennsylvania
- Cancer Care Associates of York - York
South Dakota
- Avera Cancer Institue - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2035-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07154823
The ClinicalTrials.gov registry entry for NCT07154823 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 477-participant average among 10 other Follicular Lymphoma (FL) trials with a reported enrollment target (15% higher). The listed sponsor is Tempus AI, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Follicular Lymphoma (FL) appearing as the primary indexed condition, and to 1 intervention - of which None - Observational Study is the first listed.
NCT07154823 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Maryland, Nevada, Ohio.
Frequently Asked Questions
What is clinical trial NCT07154823 about?
NCT07154823 is a clinical study titled "A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies". The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates...
What is the current status of trial NCT07154823?
This trial is currently recruiting. The enrollment target is 550 participants. The study started on 2026-01-27. Estimated completion is 2035-11.
What conditions does trial NCT07154823 study?
This clinical trial studies the following conditions: Follicular Lymphoma (FL), Acute Myeloid Leukaemia (AML).
What interventions are being tested in trial NCT07154823?
The interventions under investigation include: None - Observational Study (OTHER).
Who is sponsoring clinical trial NCT07154823?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07154823 being conducted?
This trial has 5 study locations across Maryland, Nevada, Ohio, Pennsylvania, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma (FL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RECRUITING · Phase 2
-
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
RECRUITING · Phase 3
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.